Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1396 to 1410 of 2186 results for guidelines

  1. What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical characteristics (for example, people who are seropositive, of unknown serostatus, immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to vaccination status or history of natural infection)?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    21 October 2021

  2. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (HTG386)

    Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).

    HealthTech guidance
    Published
    7 October 2015

    Sections for HTG386

  3. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    10 March 2021
    View recommendations

    Sections for TA682

  4. Self-management:- What is the impact of different early intervention-focused approaches to self-management on outcomes for older people with social care needs and multiple long-term conditions?

    Any explanatory notes(if applicable) Why this is important:- The Guideline Committee highlighted a lack of evidence on the impact of...

    Research recommendation
    Published
    11 December 2015

  5. Management of type 3c diabetes:- What is the most clinically effective and cost-effective insulin regimen to minimise hypo- and hyperglycaemia for type 3c diabetes secondary to pancreatitis?

    3c diabetes is essential to inform future updates of key recommendations in this guideline. National adoption of evidence-based insulin...

    Research recommendation
    Published
    17 December 2018

  6. In people with suspected TB, what is the relative clinical and cost effectiveness of universal andrisk-based use of rapid nucleic acid amplification tests?

    Any explanatory notes(if applicable) Why this is importantThe guideline committee noted that there were 2 possible approaches to using...

    Research recommendation
    Published
    8 November 2019

  7. Components of a mental capacity assessment:- What are the components of an effective assessment of mental capacity to make a decision (for example checklists, memory aids or standardised documentation)?

    the process and outcomes of these assessments are being recorded. The guideline committee reviewed the small amount of available...

    Research recommendation
    Published
    18 December 2018

  8. Long-term safety of ovarian stimulation and ovulation induction for women:- Is there an association between ovulation induction or ovarian stimulation and adverse long-term (over 20 years) effects in women in the UK?

    for most causes of infertility. During the course of the review for this guideline update the GDG commented on the paucity of long-term...

    Research recommendation
    Published
    9 June 2015

  9. Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received radiotherapy (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of radiotherapy Number NG162 Date issued

    Research recommendation
    Published
    21 October 2021

  10. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    10 August 2021

  11. What are the possible outcomes for people who are critically ill and have COVID-19-associated pulmonary aspergillosis (CAPA)?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    17 December 2021

  12. Lifelight First for monitoring vital signs (MIB213)

    NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .

    Medtech innovation briefing
    Published
    8 April 2020

  13. What are the most clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Do any symptoms of post‑COVID‑19 syndrome predict the need for specialist intervention? Are there clusters of symptoms that identify response to interventions in post‑COVID‑19 syndrome? What is the clinical effectiveness of different service models of multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)? What is the clinical effectiveness of exercise interventions for people with post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Does early exercise rehabilitation assist in improving symptoms of post‑COVID‑19 syndrome?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  14. What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    14 July 2022

  15. Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received systemic anticancer treatment (SACT) (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of systemic anticancer treatments Number NG161

    Research recommendation
    Published
    21 October 2021